Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes

INTRODUCTION: Delayed-release dimethyl fumarate (DMF) is an effective treatment for multiple sclerosis (MS). Some patients experience gastrointestinal (GI) adverse events (AEs) that may lead to premature DMF discontinuation. This study characterized the impact of site-specific GI management strategi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurol Ther
Autors principals: Min, Jinny, Cohan, Stanley, Alvarez, Enrique, Sloane, Jacob, Phillips, J. Theodore, van der Walt, Anneke, Koulinska, Irene, Fang, Fang, Miller, Catherine, Chan, Andrew
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534646/
https://ncbi.nlm.nih.gov/pubmed/30706431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-019-0127-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars